CXCR2 antagonists in combination with PPARγ agonists may have a synergistic role considering the latter’s proven efficacy in improving insulin sensitivity and potential in NASH treatment. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.